Emercell

EMERCell is in the process of developing a universal cell-based immunotherapy using NK cells, intended to be combined with monoclonal antibodies (MAbs) for the treatment of resistant oncology patients. This groundbreaking drug therapy, known as NK-001, comprises allogeneic Natural Killer (NK) cells that are cultured ex vivo using a patented method. NK lymphocytes possess inherent cytotoxicity as well as specific cytotoxicity when used in conjunction with MAbs (Antibody-Dependent Cell Cytotoxicity (ADCC)), and are renowned for their innate surveillance of cancer through immunology.